Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Eur J Pharm Sci ; 38(4): 355-61, 2009 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-19748575

RESUMEN

Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, which has been used as a traditional Chinese medicine due to its anti-inflammatory, analgesic or anti-pyretic action, was examined for inhibition of nucleoside transport and synergistic potentiation of methotrexate cytotoxicity. Cimicifugoside inhibited uptake of uridine, thymidine and adenosine in human leukemia U937 cells with the low nanomolar IC(50) values, but did not affect that of uracil, leucine or 2-deoxyglucose at cimicifugenin (aglycon of cimicifugoside)>bugbanoside B>cimicifugenin A, O-methyl cimicifugenin and bugbanoside A. Cimicifugoside had less affinity for the binding site of nitrobenzylthioinosine (typical high-affinity inhibitor of equilibrative nucleoside transporter-1) in U937 cells, K562 cells and human erythrocyte membranes compared with the prototype nucleoside transport inhibitor dipyridamole. Cimicifugoside markedly potentiated methotrexate cytotoxicity in a culture of U937 cells and human carcinoma KB cells. Potentiation of methotrexate cytotoxicity by cimicifugoside analogs in U937 cells was in proportion to their inhibitory activity against uridine uptake. The present study demonstrates that cimicifugoside is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity.


Asunto(s)
Cimicifuga , Lanosterol/análogos & derivados , Metotrexato/efectos adversos , Metotrexato/metabolismo , Nucleósidos/antagonistas & inhibidores , Nucleósidos/metabolismo , Triterpenos/metabolismo , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/aislamiento & purificación , Células Cultivadas , Cimicifuga/efectos de los fármacos , Sinergismo Farmacológico , Humanos , Células K562 , Lanosterol/química , Lanosterol/aislamiento & purificación , Lanosterol/metabolismo , Metotrexato/química , Transporte de Proteínas/efectos de los fármacos , Transporte de Proteínas/fisiología , Triterpenos/química , Triterpenos/aislamiento & purificación , Células U937
2.
J Mol Neurosci ; 39(3): 380-90, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19653132

RESUMEN

Neuropathic pain induced by sciatic nerve injury not only causes peripheral dysfunctions but also affects the cortical and subcortical regions of the brain. It is still unknown whether neuropathic pain could relate to behavioral and neurochemical alterations in the central nervous system. This paper deals with the effect of peripheral neuropathic pain on mechanical allodynia, neuropeptide levels, neuropeptide-degrading enzyme activities, and microglial cells in the brain regions of rats by applying chronic constriction injury, a partial sciatic nerve injury. We examined the possible protection effect on the allodynia and changes in levels of neuropeptides and microglial activation in chronic constriction injury of the rat brain by memantine. On 4 days after chronic constriction injury, the induction of mechanical allodynia was suppressed by memantine treatment. Reductions in the substance P in the hypothalamus and somatostatin in the periaqueductal gray of chronic constriction injury rat brain were reversed by memantine. This suggests the role of these neuropeptides in pain information processing in the brain. Immunohistochemical experiments revealed that the expression of CD11b, a marker protein of microglia, was increased in the hypothalamus and periaqueductal gray in the chronic constriction injury rat brain as compared with the controls, and memantine treatment could suppress the activation of microglia, suggesting the involvement of microglia in pain mechanism. The present behavioral, biochemical, and immunohistochemical studies demonstrated that peripheral neuropathic pain affects the neuropeptide levels and microglial activation in the brain regions, and these events described above may play an important role in neuropathic pain pathogenesis.


Asunto(s)
Encéfalo/efectos de los fármacos , Memantina/farmacología , Microglía/efectos de los fármacos , Neuralgia/tratamiento farmacológico , Neuropéptidos/efectos de los fármacos , Enfermedades del Sistema Nervioso Periférico/tratamiento farmacológico , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Encéfalo/metabolismo , Encéfalo/fisiopatología , Antígenos CD11/metabolismo , Modelos Animales de Enfermedad , Antagonistas de Aminoácidos Excitadores/farmacología , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/metabolismo , Hiperalgesia/fisiopatología , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Hipotálamo/fisiopatología , Masculino , Memantina/uso terapéutico , Microglía/metabolismo , Neuralgia/metabolismo , Neuralgia/fisiopatología , Neuropéptidos/metabolismo , Sustancia Gris Periacueductal/efectos de los fármacos , Sustancia Gris Periacueductal/metabolismo , Sustancia Gris Periacueductal/fisiopatología , Enfermedades del Sistema Nervioso Periférico/metabolismo , Enfermedades del Sistema Nervioso Periférico/fisiopatología , Ratas , Ratas Wistar , Neuropatía Ciática/tratamiento farmacológico , Neuropatía Ciática/metabolismo , Neuropatía Ciática/fisiopatología , Somatostatina/metabolismo , Sustancia P/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA